Actively Recruiting
Disease Progression in Women With X-linked Adrenoleukodystrophy
Led by Minoryx Therapeutics, S.L. · Updated on 2024-01-31
40
Participants Needed
1
Research Sites
178 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Observational, single-site prospective and minimally interventional study in women with X-linked adrenoleukodystrophy (ALD), conducted in France.
CONDITIONS
Official Title
Disease Progression in Women With X-linked Adrenoleukodystrophy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Women aged 18 years old or older.
- Diagnosis of X-linked ALD based on genetic testing, altered VLCFA levels, or family history.
- Willing to undergo annual follow-up visits, including brain and spinal cord MRI scans.
- Provision of written informed consent.
- Affiliation or beneficiary of a French social security system or similar regime.
You will not qualify if you...
- Any condition likely to adversely affect participation, compliance, or study results as judged by the investigator.
- Current or past treatment with leriglitazone.
- Pregnant or lactating women.
- Subjects protected by laws for vulnerable adults, including those deprived of liberty or under guardianship.
- Participation in an interventional clinical trial.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Paris Brain Institute (ICM) Centre Hospitalier Universitaire Pitié Salpêtrière
Paris, France, 75013
Actively Recruiting
Research Team
A
Arun Mistry
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here